
FDA accepts NDA for new formulation of piflufolastat F 18 in prostate cancer
On August 6, 2025, Lantheus announced that the FDA had accepted a new drug application (NDA) seeking approval of a new formulation of their PSMA-PET imaging agent, piflufolastat F 18 (Pylarify; 18F-DCFPyL) in prostate cancer.1 The application, which was …